| Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of iPSC-based Therapies |
|
| Upon completion, the acquisition will build upon Catalent’s existing induced pluripotent stem cell (iPSC) process development and manufacturing capabilities. The deal will enable Catalent to offer the building blocks to industrialize iPSC-based cell therapies while reducing barriers to entry in clinic for therapeutic companies. |
|
| Colleen Floreck, Vice President of Global Marketing and Strategy, Catalent Cell & Gene Therapy, recently discussed the deal in BioProcess International. Read the interview. |
|
| | Catalent to Develop Fast-Dissolve Zydis® Formulation for JOS Pharmaceuticals’ Cannabidiol Treatment |
|
| Catalent partners with JOS Pharmaceuticals to bring CBD treatment to patients through the Zydis® ODT format, a unique lyophilized oral tablet that dissolves in the mouth in under three seconds and without the need for water. |
|
| | | Catalent is Proud to Support Many High-Profile COVID-19 Programs Catalent has been awarded more than 80 COVID-19-related compounds including antivirals, vaccines, diagnostics and treatments across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses. Catalent is on track to deliver over one billion COVID-19 vaccine and treatment doses in 2021.
|
|
| | | Accelerate Oral Product Development and Streamline your Supply Chain with the OneXpress™ Solution
Catalent has recently announced that it had entered into a strategic agreement with CivicaScript, a non-profit organization focused on creating access to lower-cost generic medications directly to patients in hospitals or retail pharmacies, to develop a range of CivicaScript-owned generic drug abbreviated new drug applications (ANDAs). Production will take place at Catalent’s oral solids facilities in Somerset, New Jersey, and Winchester, Kentucky.
As CivicaScript’s only drug manufacturing partner for oral dose, Catalent will provide CivicaScript a comprehensive, end-to-end partnership to develop, file, scale-up and efficiently produce a range of CivicaScript-owned generic drugs. The first CivicaScript generic medicines will be available as early as 2022.
Catalent will leverage its unique OneXpress™ solution to streamline and accelerate product development and supply across Catalent’s global network. CivicaScript will benefit from scale-appropriate development from Catalent’s U.S. oral solid dose development and manufacturing site in Somerset, which also serves as the global Center of Excellence for Hot Melt Extrusion. With a single program director overseeing all aspects of the overall project, programs will be tech transferred for commercial-scale supply including final packaging to Catalent’s facility in Winchester, Catalent’s flagship U.S. manufacturing facility for large-scale oral solids. | Learn More | |
|
| Catalent Receives RoSPA Gold Award for Health and Safety Practices Catalent has received the award for working to provide a safe, healthy and inclusive working environment for its staff, customers and contractors. This is the third consecutive year that Catalent has been recognized by RoSPA in its annual awards.
| Find Out More | |
|
| Planning During a Pandemic - Endpoints Interviews Catalent
In an interview with Endpoints, Karen Flynn, President, Biologics and Chief Commercial Officer, Catalent, discusses the importance of adapting and modifying plans during a pandemic. | Read the Interview | |
|
| Catalent’s Cryogenic Storage Expansion Covered by GEN
In Genetic Engineering & Biotechnology News, Matt Blume, Vice President, Business Transformation, Catalent, discusses the company’s recent announcement that it has added cryogenic storage capabilities to its facility in Philadelphia. | Read the Interview | | Evolving Technologies - Pharma’s Almanac Roundtable
Behzad Mahdavi, Ph.D., MBA, Vice President of Open Innovation, Biologics, Cell and Gene Therapy, Catalent, recently contributed to a roundtable, published in Pharma’s Almanac, where he discussed the impact of evolving technologies such as machine learning and artificial intelligence. | Read the Article | | Catalent Supports Belgium-Based Cell and Gene Therapy Accelerator
Brussels South Charleroi BioPark (BSCB) recently announced it has launched a Cell and Gene Therapy Accelerator program to de-risk early stage research and create the advanced therapy companies of the future. Open to academic, industry or independent researchers across Europe, the program consists of an intensive bootcamp, workshops and coaching, plus access to Université libre de Bruxelles (ULB) Open BioLab and state-of-the-art technology platforms. | Find Out More |
|
| Join Our Experts at Live Virtual Events to Hear the Latest on COVID-19 and Technology Development Programs |
|
| DCAT Week 2021 | Virtual Conference | July 12-16 Join our pre-recorded video announcement presented by Karen Flynn, President, Biologics & Chief Commercial Officer, Catalent. Ms. Flynn will discuss how “Catalent Continues to Invest in Technologies and Capabilities to Serve the Global Biologics and Advanced Therapies Network”. This will be available to the DCAT membership from July 12, 2021 through July 31, 2021 via the DCAT member portal. Plus, schedule a meeting with Catalent at DCAT.
PEGS Virtual Summer Symposium | July 19-22 You’re invited on Thursday, July 22, at 10:15 a.m. ET to join Greg Bleck, Ph.D., Global Head of R&D, Catalent Biologics as he presents “Introducing GPEx® Lightning: Leveraging Proven Technology to Speed Your Path to First-In-Human Studies”.
Controlled Release Society (CRS) Annual Meeting | Virtual | July 25-29 On July 27, 2021 at 9:00 a.m. EDT, don’t miss Catalent’s Lisa Caralli, Director, Science & Technology as she presents “Strategies to Optimize the Dose Design Process to Create Better Treatments”. She will use case studies to show how the right guidance, at the right time, can help drug developers create better treatments.
CPhI North America | Philadelphia | August 10-12 Back and IN-PERSON! Our team is looking forward to meeting with you in Philadelphia during CPhI North America. Schedule a meeting.
World Orphan Drug Congress | National Harbor, Maryland | August 25 - 27 Meet with Catalent at World Orphan Drug Congress.
CAR-TCR Summit Boston | Virtual | August 31 - September 2 Meet with Catalent at CAR-TCR Summit. |
|
| A Catalyst in Drug Development |
|
| Dejan Lamesic, Ph.D. Product Development Scientific Team Leader - Schorndorf, Germany |
|
| Dr. Lamesic specializes in the material science of excipients, specifically fillers and polymers for immediate and controlled-release solid dosage forms. His expertise in particle engineering and the compaction process includes tableting and dry granulation. Discover what drives Dejan’s passion for pharmaceutical materials science: read his published works including peer-reviewed articles and register for his upcoming webinar. |
|
|
|
| | | | Biologics Development and Manufacturing Explore Catalent’s Biologics capabilities at its Kansas City facility by taking a 360° Virtual Tour. This is a Center-of-Excellence for the company’s Biologics Analytical Services business. The team has over 25 years of experience providing broad-based and orthogonal analytical CMC services for stand-alone and integrated biologics projects. |
|
| | Consumer Health Take a 360° Virtual Tour of Catalent’s facility in Aprilia, Italy. This site is a Center-of-Excellence for softgel development and manufacturing for both oral and topical dose forms. This site features innovative technologies for Pharmaceuticals, Over-The-Counter, Nutritional Supplements and Topical Beauty. | | Oral Development and Manufacturing In this 360° Virtual Tour, view Catalent’s facility in Schorndorf, Germany, the flagship EU manufacturing location for large-scale reliable supply of complex controlled release oral solid dose forms through state-of-the-art fluid bed granulation capabilities, integrated development, commercial manufacture and packaging. |
| We are the Catalyst for your Success. Join Us! |
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana; Madison, Wisconsin; Harmans, Maryland; Kansas City, Missouri; and more. Visit www.catalent.com/careers for more information.
|
|
| |
|
Every brand has a challenge. We have a solution. |
|
| | or call +1 877 891 9609 to speak with one of our experts today! |
|
| |
|
To unsubscribe or manage your subscriptions, please click here. For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2021, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|